Document is current

Article History

Received: 30 May 2022

Accepted: 26 January 2023

First Online: 24 February 2023

Competing interests

: The Authors declare no Competing Non-Financial Interests but the following Competing Financial Interests: G.C. declares that he has received personal fees for his participation in the PROCURE Project as a member of the Steering Committee and his role as coordinator of the study. He also reports advisory board roles for Pfizer, Novartis, Lilly, Seagen, Amgen, Roche, Astra Zeneca, Daichii Sankyo, Celcuity, Veracyte and Gilead outside the submitted work. He has also received institutional financial support for clinical trials from: Amgen, Astra-Zeneca, Boehringer-Ingelheim, Bristol-Myers-Squibb, Bayer, Daiichi-Sankyo, GlaxoSmithKline, Incyte, Nektar Therapeutics, Novartis, Macrogenics, Merck, Pfizer, Pierre-Fabre, Roche, Sanofi-Aventis, Taiho Oncology, Tesaro, Blueprint, Seagen. F.C. declares that she has not received any economic compensation for her participation in the PROCURE Project. She declares advisory/consultancy role for: Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Debiopharm, Eisai, GE Oncology, Genentech, Gilead, GlaxoSmithKline, Iqvia, Macrogenics, Medscape, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, prIME Oncology, Roche, Sanofi, Samsung Bioepis, Seagen, Teva, Touchime. She has also received institutional financial support for clinical trials from: Amgen, Astra-Zeneca, Boehringer-Ingelheim, Bristol-Myers-Squibb, Bayer, Daiichi, Eisai, Fresenius GmbH, Genentech, GlaxoSmithKline, Ipsen, Incyte, Nektar Therapeutics, Nerviano, Novartis, Macrogenics, Medigene, MedImmune, Merck, Millenium, Pfizer, Pierre-Fabre, Roche, Sanofi-Aventis, Sonus, Taiho Oncology, Tesaro, Tigris, Wilex, Wyeth. M.G. declares that he has received personal fees for his participation in the PROCURE Project as a member of the Steering Committee. He also reports personal fees/travel support from Amgen, DaiichiSankyo, AstraZeneca, EliLilly, LifeBrain, Nanostring, Novartis, PierreFabre, MSD; an immediate family member is employed by Sandoz. N.H. declares that she has received personal fees for her participation in the PROCURE Project as a member of the Steering Committee. She also declares that she has received honoraria for lectures and/or consulting from Amgen, AstraZeneca, Daiichi-Sankyo, Exact Sciences, Gilead, Lilly, MSD, Novartis, Pierre-Fabre, Pfizer, Roche, Sandoz, and Seagen. J.K. declares that she has received personal fees for her participation in the PROCURE Project as a member of the Steering Committee. She also reports advisory role for Roche, Pfizer, AstraZeneca, Gilead, and Lilly and speaker bureau roles for Pfizer, Roche, Seagen, and Novartis. A.V.L. declares that she has received personal fees for her participation in the PROCURE Project as a member of the Steering Committee. She also reports advisory board roles for AstraZeneca, Novartis, and MSD. She has also received institutional research funding from Novartis and AstraZeneca. F.P.L. declares that she has received personal fees for her participation in the PROCURE Project as a member of the Steering Committee. She also declares fees from AbbVie, Agendia, Astellas, AstraZeneca, Bayer, BMS, Eisai, Exact Sciences, GSK, Janssen, Lilly, MERCK Life, MSD, Myriad, Novartis, Pfizer, Pierre-Fabre, Roche, Sanofi, Servier, Veracyte. A.P. declares that he has received personal fees for his participation in the PROCURE Project as a member of the Steering Committee. He also declares that he has received lecture fees from Roche, Pfizer, Novartis, Amgen, BMS, Nanostring Technologies, and Daiichi Sankyo; advisory role/consultancy fees from Roche, Pfizer, Novartis, Amgen, BMS, Puma, Oncolytics Biotech, MSD, Guardan Health, Peptomyc and Lilly; and fees for leadership role from Reveal Genomics, SL. He has also received fees for research from Boehringer, Novartis, Roche, Nanostring, Sysmex Europa GmbH, Medica Scientia inno. Research, SL, Celgene, Astellas and Pzifer; lecture fees from Nanostring technologies and fees for developing clinical trials from Boehringer, Lilly, Roche, Novartis, Amgen and Daiichi Sankyo. Finally, he has received fees for his leadership role in executive boards for Reveal Genomics, SL and SOLTI cooperative group and for participating in a patronage committee for SOLTI Foundation and Actitud Frente al Cáncer Foundation.